Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
about
Pharmacogenomics of chemotherapeutic susceptibility and toxicityMixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancerUnderstanding human variation in infectious disease susceptibility through clinical and cellular GWAS.EPS8 inhibition increases cisplatin sensitivity in lung cancer cells.Genetic variation is the major determinant of individual differences in leukocyte endothelial adhesion.Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationWhole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.Relating human genetic variation to variation in drug responses.Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cellsGenetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.CXCL12 Mediates Aberrant Costimulation of B Lymphocytes in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Immunodeficiency.Open source machine-learning algorithms for the prediction of optimal cancer drug therapies.Functional consequences of PRPF39 on distant genes and cisplatin sensitivity.
P2860
Q27025558-6E97C9CD-DE51-483F-AFCC-3DB89E487708Q28480587-A2F7714B-076C-4BE4-8337-DD9DD0C462C8Q34916760-BF73736A-0941-414E-9799-9C1AC57590C6Q35075274-1EF3E7CD-E661-4575-B145-A16DB1AA16ADQ35092664-498EB95F-9E73-486C-BA6F-E7473C7115DDQ35799841-CD48AFFD-7765-4DFC-BB58-F4B0B00388B1Q36035404-7D4BB541-5959-4FFE-9EE3-6AA97585850DQ36252524-BA114CC2-3E13-43E8-87B9-B6F3D84D520FQ36873301-2F7A081C-0D07-4B62-82C6-79EC04C64BF5Q36877796-2D1690E3-6A9A-4383-8572-9B5FE42298ACQ37299680-D0FB8D04-C8C2-4011-BBC8-0F269568E0ADQ39321548-29DA32B1-93F7-4028-B511-49E8258DCED1Q41475522-DCD8DCD5-F8BA-4ECD-83D1-A424CCF52E9AQ42699335-42DFB2BA-9958-40E4-A966-35D66301C15FQ43072148-BDAB6181-60C5-44B6-8A37-3EA0279B6F6E
P2860
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
@ast
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
@en
type
label
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
@ast
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
@en
prefLabel
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
@ast
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
@en
P2093
P2860
P921
P1476
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies
@en
P2093
Dana M Ziliak
Lidija K Gorsic
Mary Eileen Dolan
P2860
P304
P356
10.1097/FPC.0B013E3283481967
P577
2011-08-01T00:00:00Z